Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by Law.com, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!

X

Wilkinson and Walsh of Paul Weiss notch summary judgment win for Pfizer

Wilkinson and Walsh of Paul Weiss notch summary judgment win for Pfizer

Walsh and Wilkinson

Paul Weiss litigation partners Beth Wilkinson and Alexandra Walsh were part of a team that recently achieved a victory for Pfizer Inc. when a federal court granted the company’s motion for summary judgment. The U.S. District Court for the Southern District of New York ruling in In Re Pfizer Inc. Securities Litigation dismissed the securities class action case in its entirety, according to the firm. The litigation involved decade-old disclosures related to Celebrex and Bextra.

“This was a major victory after a decade-long fight against these allegations,” Walsh told WIPL. “We are extremely gratified that the court recognized the fundamental deficiencies in the plaintiffs’ claims and dismissed the case before trial.”

The ruling by U.S. District Judge Laura Taylor Swain came ahead of a Sept. 9 trial in the case, which investors launched in 2004. It followed an earlier ruling precluding testimony by the plaintiffs’ damages expert.

“We are thrilled about the outcome,” said Wilkinson. “And it was especially satisfying to work again with Pfizer’s top-notch legal team.”

Wilkinson focuses her practice on general litigation and has amassed a broad range of experience, with a particular emphasis in white-collar criminal defense, internal investigations, product liability and complex civil litigation.

Walsh focuses her practice on securities and white collar criminal litigation at the trial and appellate level. She also focuses on internal corporate investigations, including those involving potential issues under the Foreign Corrupt Practices Act.

Contributing Author

author image

Amy I. Stickel

Amy I. Stickel has extensive experience covering the legal, financial and pharmaceutical industries as a writer and editor. A past managing editor of Corporate Legal Times and...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.